Die ewig steigende Aktie Nr.2 (Seite 8)
eröffnet am 11.07.13 22:47:56 von
neuester Beitrag 22.02.24 11:29:09 von
neuester Beitrag 22.02.24 11:29:09 von
Beiträge: 101
ID: 1.183.735
ID: 1.183.735
Aufrufe heute: 0
Gesamt: 18.541
Gesamt: 18.541
Aktive User: 0
ISIN: DK0060448595 · WKN: A1KAGC · Symbol: CBHD
120,90
EUR
+0,50 %
+0,60 EUR
Letzter Kurs 19.04.24 Tradegate
Neuigkeiten
08.03.24 · globenewswire  |
06.03.24 · globenewswire |
06.03.24 · globenewswire |
01.03.24 · globenewswire |
28.02.24 · globenewswire |
Werte aus der Branche Chemie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6905 | +18,74 | |
| 31,08 | +10,41 | |
| 0,6634 | +10,14 | |
| 16,480 | +10,01 | |
| 5,9600 | +9,96 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 37,05 | -12,37 | |
| 1,0100 | -22,31 | |
| 5,6900 | -26,68 | |
| 6,2500 | -33,16 | |
| 43,02 | -60,46 |
Beitrag zu dieser Diskussion schreiben
Feedback
Starke Zahlen bringen heute ein Kursplus von 5% 
Coloplast A/S: Coloplast raises guidance for full-year growth
Despite provision for litigation in the USA, Coloplast delivers strong results for the first six months of the 2013/14 financial year, generated revenue of DKK 6,080 million and delivered organic growth of 10%. The half-year results are affected by the provision of DKK 1bn to cover potential settlements and other costs in connection with litigation in the US that was announced on May 2 2014. The provision is recorded as special items.
EBIT before special items was up by 14% to DKK 1,997 million, with an EBIT margin before special items of 33% compared with 31% in the first quarter of last year.
Strong first-half performance "We're presenting a strong first-half performance despite the provision for litigation in the USA. We have continued to build on an excellent start of the financial year and have managed to maintain our momentum, so once again we are delivering solid growth in all business areas and all regions, and I'm very pleased with our first half-year performance," says Coloplast CEO Lars Rasmussen.
Sales growth by business area was as follows: Ostomy Care 9%, Continence Care 11%, Urology Care 10% and Wound & Skin Care 11%. Coloplast grew its European business by 7%, Other Established Markets by 11% and Emerging Markets by 25%.
"We're very pleased to see sales continuing to improve in our Urology Care and Wound Care businesses," says Lars Rasmussen, and he continues: "I'm also very pleased with our growth performance in the US market, which is an important market for us, and with our results in China and Brazil."
Guidance for 2013/2014 upgraded and interim dividend determined Based on its strong first-half performance and the generally growing momentum of the business, Coloplast is upgrading its guidance for full-year organic growth from about 8% to about 9%. Revenue growth in DKK is now expected to be about 7% (previously about 6%). The EBIT margin before special items guidance is also being upgraded to 33-34% at constant exchange rates (from previously about 33%), but maintained at 33% in DKK.
An EBIT margin of 25-26% at constant exchange rates and around 25% in DKK is expected.
The Board of Directors has resolved that the company will pay an interim dividend of DKK 4 per share following the release of the first-half financial statements, for a total dividend payout of DKK 844 million.
The payout is a consequence of the amended dividend policy Coloplast announced last year, according to which the company pays dividends twice a year, i.e. after the AGM and after the release of the half-year interim report.
For further information, click here to read the H1 Interim Report.
PRESS CONTACT Simon Mehl Augustesen Media Relations Manager +45 4911 3488 dksia@coloplast.com
INVESTOR RELATIONS Ian Christensen Vice President, Investor Relations +45 4911 1301 dkisec@coloplast.com
Financial highlights and key ratios
Financial highlights and key ratios 6M 6M Change FY 2012/13 (DKKm) 2013/14 2012/13 Revenue 6,080 5,707 7% 11,635 EBIT 1,997 1,756 14% 3,672 EBIT margin 33% 31% 2%-p.p. 32% Special items 1.000 - - -
EBIT after 997 1,756 (43%) 3,672 special items EBIT margin after 16% 31% (15 p.p.) 32% special items
Sales performance by business 6M 6M Organic Reported areas 2013/14 2012/13 growth growth DKKm DKKm Ostomy Care 2,491 2,385 9% 4% Continence Care 2,159 1,990 11% 8% Urology Care 594 556 10% 7% Wound & Skin Care 836 776 11% 8% Revenue 6,080 5,707 10% 7%
Attachment:
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServ…
© 2014 GlobeNewswire
Coloplast A/S: Coloplast raises guidance for full-year growth
Despite provision for litigation in the USA, Coloplast delivers strong results for the first six months of the 2013/14 financial year, generated revenue of DKK 6,080 million and delivered organic growth of 10%. The half-year results are affected by the provision of DKK 1bn to cover potential settlements and other costs in connection with litigation in the US that was announced on May 2 2014. The provision is recorded as special items.
EBIT before special items was up by 14% to DKK 1,997 million, with an EBIT margin before special items of 33% compared with 31% in the first quarter of last year.
Strong first-half performance "We're presenting a strong first-half performance despite the provision for litigation in the USA. We have continued to build on an excellent start of the financial year and have managed to maintain our momentum, so once again we are delivering solid growth in all business areas and all regions, and I'm very pleased with our first half-year performance," says Coloplast CEO Lars Rasmussen.
Sales growth by business area was as follows: Ostomy Care 9%, Continence Care 11%, Urology Care 10% and Wound & Skin Care 11%. Coloplast grew its European business by 7%, Other Established Markets by 11% and Emerging Markets by 25%.
"We're very pleased to see sales continuing to improve in our Urology Care and Wound Care businesses," says Lars Rasmussen, and he continues: "I'm also very pleased with our growth performance in the US market, which is an important market for us, and with our results in China and Brazil."
Guidance for 2013/2014 upgraded and interim dividend determined Based on its strong first-half performance and the generally growing momentum of the business, Coloplast is upgrading its guidance for full-year organic growth from about 8% to about 9%. Revenue growth in DKK is now expected to be about 7% (previously about 6%). The EBIT margin before special items guidance is also being upgraded to 33-34% at constant exchange rates (from previously about 33%), but maintained at 33% in DKK.
An EBIT margin of 25-26% at constant exchange rates and around 25% in DKK is expected.
The Board of Directors has resolved that the company will pay an interim dividend of DKK 4 per share following the release of the first-half financial statements, for a total dividend payout of DKK 844 million.
The payout is a consequence of the amended dividend policy Coloplast announced last year, according to which the company pays dividends twice a year, i.e. after the AGM and after the release of the half-year interim report.
For further information, click here to read the H1 Interim Report.
PRESS CONTACT Simon Mehl Augustesen Media Relations Manager +45 4911 3488 dksia@coloplast.com
INVESTOR RELATIONS Ian Christensen Vice President, Investor Relations +45 4911 1301 dkisec@coloplast.com
Financial highlights and key ratios
Financial highlights and key ratios 6M 6M Change FY 2012/13 (DKKm) 2013/14 2012/13 Revenue 6,080 5,707 7% 11,635 EBIT 1,997 1,756 14% 3,672 EBIT margin 33% 31% 2%-p.p. 32% Special items 1.000 - - -
EBIT after 997 1,756 (43%) 3,672 special items EBIT margin after 16% 31% (15 p.p.) 32% special items
Sales performance by business 6M 6M Organic Reported areas 2013/14 2012/13 growth growth DKKm DKKm Ostomy Care 2,491 2,385 9% 4% Continence Care 2,159 1,990 11% 8% Urology Care 594 556 10% 7% Wound & Skin Care 836 776 11% 8% Revenue 6,080 5,707 10% 7%
Attachment:
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServ…
© 2014 GlobeNewswire
Antwort auf Beitrag Nr.: 46.818.981 von Raibabänker am 14.04.14 10:40:16Konkrete Gründe gibt es glaube ich nicht.
Aber wie bereits gesagt ist Coloplast in der jüngsten Vergangenheit sehr gut gelaufen - ein bisschen zu gut.
Da sind Korrekturen nicht verwunderlich, zumal der Gesamtmarkt aktuell ähnlich reagiert.
Aber wie bereits gesagt ist Coloplast in der jüngsten Vergangenheit sehr gut gelaufen - ein bisschen zu gut.
Da sind Korrekturen nicht verwunderlich, zumal der Gesamtmarkt aktuell ähnlich reagiert.
Gibt es Gründe für den heutigen Kursrückgang?
Auch in den letzten Wochen schwächselte Coloplast. Vor einem guten Monat notierte Coloplast bei 62 Euro. Heute notiert Coloplast gut 11% schwächer bei 54,90 Euro.
Auch in den letzten Wochen schwächselte Coloplast. Vor einem guten Monat notierte Coloplast bei 62 Euro. Heute notiert Coloplast gut 11% schwächer bei 54,90 Euro.
Und damit haben wir mal wieder einen Match... 
Habe heute eine erste Position aufgebaut.
Trading Spotlight
Die Performance von Coloplast in 2014 ist ja sehr beachtlich, leider bin ich noch nicht mit an Bord. 
Inzwischen würde ich die Aktie aber auch bereits als heißgelaufen bezeichnen und ich werde eher auf einen Rücksetzer warten...
Inzwischen würde ich die Aktie aber auch bereits als heißgelaufen bezeichnen und ich werde eher auf einen Rücksetzer warten...
Im Mai wurde eine Sonderdividende gezahlt, keine Zwischendividende.
Antwort auf Beitrag Nr.: 46.408.394 von Cameltrophy am 08.02.14 20:44:55Also ich meine, ich hätte das auch irgendwo gelesen. Auf der coloplast Webseite steht allerdings nur ein Dividendentermin.
2014
08.1.Closing Period until 29 January
29.1.Interim Financial Statements for Q1 2013/14
07.4.Closing period until 7 May
07.5.Interim Financial Statements for H1 2013/14
04.6.Capital Market Day
07.7.Closing period until 13 August
13.8.Interim Financial Statements for 9M 2013/14
06.10.Closing period until 30 October
22.10.Notice of submission of agenda points for the Annual General Meeting
30.10.Financial Statements for the full year 2013/14 and Annual Report 2013/14
04.12.Annual General Meeting
10.12.Dividends for 2013/14 at the disposal of shareholders
Siehe http://www.coloplast.com/investor-relations/financial-calend…
2014
08.1.Closing Period until 29 January
29.1.Interim Financial Statements for Q1 2013/14
07.4.Closing period until 7 May
07.5.Interim Financial Statements for H1 2013/14
04.6.Capital Market Day
07.7.Closing period until 13 August
13.8.Interim Financial Statements for 9M 2013/14
06.10.Closing period until 30 October
22.10.Notice of submission of agenda points for the Annual General Meeting
30.10.Financial Statements for the full year 2013/14 and Annual Report 2013/14
04.12.Annual General Meeting
10.12.Dividends for 2013/14 at the disposal of shareholders
Siehe http://www.coloplast.com/investor-relations/financial-calend…
Antwort auf Beitrag Nr.: 46.422.356 von Groppi am 11.02.14 11:21:34Sorry, wollte natürlich schreiben "erstklassiger Demografie-Profiteur".
Hallo, die Umstellung auf 2-malige Divi-Zahlung/Jahr ist korrekt. Coloplast ist ein erstmaliger Demografie-Profiteur. Die Aktie werde ich in den nächsten 10 Jahren auf jeden Fall in meinem Depot belassen und in Schwächephasen weiter aufstocken.
Durchsuchen
